“Annovis Bio delivers candor on its Parkinson’s study, even if it doesn’t inspire much confidence”

[ZebraDoodle]

Paywall - but link posted in case someone has access and can provide a précis

statnews.com/2024/02/23/ann...

[MBAnderson]

The article requires payment. What point does it make?

[Bolt_Upright]

I found some of the story here: "Annovis Bio’s candor about late trial design change

It was a controversial choice for Annovis Bio to change the endpoint of a Phase 3 Parkinson’s trial at the last minute. STAT’s Adam Feuerstein, ever skeptical, reached out to CEO Maria Maccecchini to learn why: Apparently the FDA suggested Annovis a more appropriate primary outcome measure, changing gears from before. “We were confused,” Maccecchini told STAT, describing the company’s efforts by this point as a “Hail Mary” approach.

So although the late changes to the trial’s design don’t smack of spin, as Adam initially had supposed, the CEO’s candor doesn’t exactly inspire confidence in the company’s ability to deliver positive results."

statnews.com/2024/02/23/bio...

[Ed-shakes]

yes is not looking good unfortunately:

seekingalpha.com/article/46...

They also mentioned a point I was not aware of about this medicine not being the first one to reduce and target alpha synucleos yet show no clinical results.

[limcheeese22]

does that mean a reduction of α-synuclein will improve symptoms?

[Ed-shakes in reply to limcheeese22]

That hasn’t been proven yet

[ZebraDoodle]

bit more here: medriva.com/health/annovis-...

[WinnieThePoo]

As someone who was on a 2 year trial for a monoclonal alpha synuclein antibody trial, this is no big surprise. It would be wonderful if buntanetap made an important difference to parkinson's disease but I won't hold my breath

[limcheeese22]

seekingalpha.com/article/46...

some relative positive new